Transpara
The breast screening AI tested in Sweden's MASAI trial, where AI-supported reading found more cancers and nearly halved the radiologists' workload.
Overview
Transpara (ScreenPoint Medical, Nijmegen) is CE-marked and FDA 510(k)-cleared for 2D mammography (2018) and digital breast tomosynthesis (2020). It was the software used in the MASAI randomised trial of 80,000 women in Sweden: the interim analysis (Lancet Oncology 2023) reported a cancer detection rate of 6.1 per 1,000 with AI-supported screening versus 5.1 per 1,000 with standard double reading, similar recall rates, and a 44.3% reduction in screen-reading workload. Transpara is deployed in screening programmes in Sweden, Denmark, Germany and elsewhere, and its use as one of two readers is the model the NHS is evaluating in the EDITH trial.
Approvals
| Region | Year | Indication |
|---|---|---|
| EU | 2017 | CE mark, mammography decision support |
| US | 2018 | 510(k) clearance, 2D mammography |
| US | 2020 | 510(k) clearance, digital breast tomosynthesis |
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials in OnCo
Notes
top- What a result means: the AI does not give a diagnosis; a high score prompts closer radiologist review or recall for further imaging, and a low score can let a programme use one human reader instead of two.
Latest papers
topQuery for this drug: (TITLE:"Transpara" OR ABSTRACT:"Transpara") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Transpara, not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductLunit INSIGHT MMG
Shares Mammography & tomosynthesis, AI in radiology, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag test.
- ProductProFound AI (iCAD)
Shares Mammography & tomosynthesis, AI in radiology, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag test.
- ProductMia (Mammography Intelligent Assessment)
Shares Mammography & tomosynthesis, AI in radiology, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag test.
- ProductRaDaR
Shares Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag test.
- ProductOptellum Virtual Nodule Clinic
Shares AI in radiology and the tag test.
- ProductBRACAnalysis CDx
Shares Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag test.
- ProductHER2 IHC and ISH companion assays (HercepTest, PATHWAY 4B5, HER2 Dual ISH)
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tag test.
- ProductBreast Cancer Index
Shares HR-positive / HER2-negative breast cancer and the tag test.